NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Receives Consensus Recommendation of “Hold” from Analysts

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) has been assigned a consensus rating of “Hold” from the five brokerages that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $1.9833.

A number of research firms have recently weighed in on NMTC. Wall Street Zen raised NeuroOne Medical Technologies to a “sell” rating in a research report on Saturday, February 21st. Zacks Research cut NeuroOne Medical Technologies from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 13th. Finally, JonesTrading initiated coverage on NeuroOne Medical Technologies in a report on Monday, March 2nd. They set a “buy” rating and a $1.50 price target on the stock.

NeuroOne Medical Technologies Stock Performance

Shares of NMTC stock opened at $0.76 on Friday. NeuroOne Medical Technologies has a fifty-two week low of $0.40 and a fifty-two week high of $1.16. The company has a 50 day moving average price of $0.79 and a 200 day moving average price of $0.79. The stock has a market capitalization of $38.41 million, a P/E ratio of -4.47 and a beta of 0.74.

NeuroOne Medical Technologies (NASDAQ:NMTC) last released its earnings results on Tuesday, February 17th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.01. NeuroOne Medical Technologies had a negative net margin of 78.34% and a negative return on equity of 119.92%. The company had revenue of $2.89 million for the quarter, compared to analyst estimates of $2.47 million.

Insider Activity at NeuroOne Medical Technologies

In related news, insider David J. Wambeke acquired 1,000,000 shares of the stock in a transaction dated Sunday, March 1st. The stock was acquired at an average cost of $0.67 per share, with a total value of $670,000.00. Following the completion of the transaction, the insider owned 1,000,000 shares in the company, valued at $670,000. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders sold 14,637 shares of company stock worth $11,710 over the last three months. Insiders own 11.80% of the company’s stock.

Institutional Trading of NeuroOne Medical Technologies

Hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd lifted its stake in NeuroOne Medical Technologies by 321.1% in the fourth quarter. XTX Topco Ltd now owns 85,454 shares of the company’s stock worth $65,000 after acquiring an additional 65,163 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in shares of NeuroOne Medical Technologies in the 4th quarter valued at approximately $36,000. Essex Investment Management Co. LLC acquired a new stake in shares of NeuroOne Medical Technologies in the 4th quarter valued at $143,000. Renaissance Technologies LLC lifted its position in shares of NeuroOne Medical Technologies by 10.2% during the 4th quarter. Renaissance Technologies LLC now owns 763,028 shares of the company’s stock worth $578,000 after purchasing an additional 70,428 shares during the last quarter. Finally, Legato Capital Management LLC purchased a new stake in shares of NeuroOne Medical Technologies during the 4th quarter worth $34,000. Institutional investors and hedge funds own 16.07% of the company’s stock.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.